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Background: Chronic respiratory diseases and use of antiasthmatic medication during
pregnancy may both play a role in the etiology of congenital anorectal malformations
(ARM). However, it is unclear, whether the medication use or the underlying condition
would be responsible. Therefore, our aim was to unravel the role of maternal chronic
respiratory diseases from that of antiasthmatic medication in the etiology of ARM.
Methods: We obtained 412 ARM patients and 2,137 population-based controls from the
Dutch AGORA data- and biobank. We used maternal questionnaires and follow-up tele-
phone interviews to obtain information on chronic respiratory diseases, antiasthmatic medi-
cation use, and potential confounders. Multivariable logistic regression analyses were
performed to estimate odds ratios (ORs) with 95% confidence intervals (95% CI).
RESULTS: We observed higher risk estimates among women with chronic respi-
ratory diseases with and without medication use (1.4 [0.8–2.7] and 2.0 [0.8–5.0]),
both in comparison to women without a chronic respiratory disease and without
medication use. Furthermore, increased ORs of ARM were found for women using
rescue medication (2.4 [0.8–7.3]) or a combination of maintenance and rescue
medication (2.5 [0.9–6.7]). In addition, increased risk estimates were observed for
women having nonallergic triggers (2.5 [1.0–6.3]) or experiencing exacerbations
during the periconceptional period (3.5 [1.4–8.6]).
CONCLUSIONS: Although the 95% CIs of most associations include the null value,
the risk estimates all point towards an association between uncontrolled chronic respira-
tory disease, instead of antiasthmatic medication use, with ARM in offspring. Further
in-depth studies towards mechanisms of this newly identified risk factor are warranted.
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1 | INTRODUCTION
Anorectal malformations (ARM) are one of the most fre-
quently observed birth defects of the digestive system and are
characterized by a disturbed embryonic hindgut development
during weeks 4–8 after conception. The prevalence ranges
from 2 to 7 patients per 10,000 pregnancies worldwide,
(InternationalClearinghouse, 2014) with severity ranging from
ARM with or without perineal fistula to complex cloacal
malformations (Holschneider et al., 2005). Additional birth
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defects, such as defects of the genitourinary system or defects
that are part of the VACTERL (Vertebral, Anal, Cardiac,
Tracheo-Esophageal, Renal, and Limb defects) association, are
observed in approximately 50% of ARM patients (Cuschieri &
EurocatWorkingGroup, 2002; Stoll, Alembik, Dott, & Roth,
2007). Several nongenetic factors have been associated with
ARM, such as assisted reproductive techniques (ART), twin
pregnancies, maternal overweight, preexisting diabetes, and
previous miscarriage (van de Putte et al., 2017; Wijers, van
Rooij, et al., 2014). However, as these factors do not explain
ARM in the majority of patients (Wijers, van Rooij, et al.,
2014), the knowledge about the etiology of ARM is still far
from complete.
Asthma is a common chronic disease among pregnant
women (Kwon, Belanger, & Bracken, 2003; Murphy, 2015).
Maternal asthma seems to be associated with increased risks
of adverse birth outcomes, such as preterm birth, low birth-
weight, and birth defects, specifically of the central nervous
system, respiratory system, digestive system, as well as cleft
lip with or without cleft palate (Blais & Forget, 2008; Blais,
Kettani, Elftouh, & Forget, 2010; Demissie, Breckenridge, &
Rhoads, 1998; Murphy et al., 2013). As asthma exacerbations
occur in approximately 45% of women with asthma during
pregnancy, guidelines emphasize asthma management to pre-
vent exacerbations (Murphy, 2015; NAEPP expert panel
report, 2005; National Asthma Education and Prevention Pro-
gram Asthma and Pregnancy Working Group, 2005). How-
ever, the influence of asthma and antiasthmatic medication on
the risks of ARM in offspring remains unclear. Wijers
et al. (2013) showed an increased risk of ARM in offspring
among women with chronic obstructive lower pulmonary dis-
eases, for example, asthma and bronchitis, in a registry-based
study. Zwink, Rissmann, Potzsch, Reutter, and Jenetzky
(2016) showed a stronger association between ARM in off-
spring and maternal respiratory diseases. However, the results
of both studies may have been influenced by antiasthmatic
medication use among women with respiratory diseases.
The use of antiasthmatic medication during pregnancy is
generally considered safe (Blais, Beauchesne, Rey, Malo, &
Forget, 2007; Eltonsy, Kettani, & Blais, 2014). Nevertheless,
several studies showed an increased risk of ARM (Garne et al.,
2016; Kallen & Otterblad Olausson, 2007; Lin et al., 2012).
Kallen & Otterblad Olausson (2007) showed an association
between ARM and the use of antiasthmatic medication in early
pregnancy, especially inhaled corticosteroid use, in a Swedish
cohort study (1995–2004). In a subsequent study in the same
population (1996–2011), however, the risk estimate was
reduced (Kallen, 2014). Lin et al. (2012) detected an increased
risk of isolated ARM in women using antiasthmatic medication
in the periconceptional period, as did Garne et al. (2016) in a
meta-analysis of three cohort studies.
These studies claimed that it was difficult to disentangle
the role of chronic respiratory diseases in these associations
from that of their pharmacological treatment. Therefore, we
performed a case–control study to investigate the association
between maternal chronic respiratory diseases and ARM in
offspring separately from the association between antiasth-
matic medication and the occurrence of ARM.
2 | METHODS
2.1 | Study population
We obtained patients with ARM and healthy controls from the
AGORA (Aetiologic research into Genetic and Occupational/
environmental Risk factors for Anomalies in Children) data-
and biobank of the Radboud university medical center
(Radboudumc) in the Netherlands. AGORA includes clinical
and questionnaire data, as well as DNA samples from children
with birth defects or childhood cancer, population-based control
children, and their parents (van Rooij et al., 2016). A pediatric
surgeon, a clinical geneticist, and the researchers collaboratively
reviewed the medical records of ARM patients to obtain clinical
information on ARM, the diagnosis of other birth defects, and
known genetic causes. The ARM phenotypes were classified
according to the Krickenbeck criteria (Holschneider et al.,
2005). The EUROCAT classification for birth defects was used
to differentiate between additional minor and major birth defects
that were present within our patients (EUROCAT Guide 1.3
and reference documents, 2005).
From 2007 onward, pediatric surgeons asked parents of
ARM patients to participate in AGORA at the child's first visit
to the Radboudumc. They were invited by regular mail when
their child was treated in the Pediatric Surgery Department of
the Erasmus Medical Center Rotterdam or the University Medi-
cal Center Groningen. The parents were asked to fill out a ques-
tionnaire concerning information on demographics, family
history, and health and lifestyle before and during pregnancy.
We excluded ARM patients with a family history of ARM, a
known genetic syndrome, a chromosomal abnormality, or a clo-
acal extrophy, whereas we included ARM patients with other
birth defects in the study. Our population-based controls were
randomly sampled in 2010–2011 via 39 municipalities in geo-
graphical areas comparable to those of the patients. They were
born between January 1990 and March 2011 and were of simi-
lar age as our patient group. Based on the questionnaire data,
we excluded controls with major birth defects, a known genetic
syndrome, or a chromosomal abnormality.
The Regional Committee on Research Involving Human
Subjects Arnhem-Nijmegen approved the AGORA study
protocol in 2006, and all participants and/or their parents
provided written informed consent.
2.2 | Data collection
Maternal questionnaires provided information about the
presence of chronic respiratory diseases, such as asthma or
chronic bronchitis, and the use of antiasthmatic medication.
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We asked the women about the presence of any chronic dis-
ease in the 3 months before or during pregnancy. In addi-
tion, they were asked whether medication for asthma and/or
chronic bronchitis was used, including the name of the medi-
cation, and the specific period in pregnancy in which the
medication was used.
In addition, we conducted telephone interviews with
women who reported a chronic respiratory disease and/or
antiasthmatic medication use, and with women for whom
this information remained unclear in the questionnaire. We
assumed that women who clearly reported no chronic respi-
ratory disease and no use of antiasthmatic medication did
not have a chronic respiratory disease, so these women were
not interviewed. The interview focused on clarifying missing
information and obtaining more detailed information not yet
assessed in the questionnaire, such as the self-reported fre-
quency of periconceptional antiasthmatic medication use
(rescue use vs. maintenance use), type of trigger (allergic
vs. nonallergic), and exacerbations in the periconceptional
period (defined as no control over the chronic respiratory
disease in the 3 months before pregnancy, deterioration of the
respiratory disease during the first trimester, or experiencing
asthma complaints during the entire periconceptional period).
Within this study, the periconceptional period was defined as
the 3 months before conception until the 10th week of preg-
nancy, as anorectal development is complete by that time
(Schoenwolf et al., 2015). The antiasthmatic medication was
reported to be used to treat asthma or chronic bronchitis and
included inhaled corticosteroids, beta2-adrenergic agonists,
anticholinergics, cromoglicic acids, and leukotriene receptor
antagonists. Antiallergic medication was not included as anti-
asthmatic medication.
As both the maternal questionnaire and the telephone inter-
view generated self-reported data, we combined these two data
sources to assess the presence of chronic respiratory diseases
and antiasthmatic medication use. In case of discrepancies, we
assumed the telephone interview to be more reliable, because
the latter was based on more in-depth questions.
We extracted information on infant and maternal characteris-
tics from the maternal questionnaires. Infant characteristics
included gender, year of birth, descent (Dutch vs. non-Dutch),
low birthweight (<2,500 g), and preterm delivery (<37 weeks).
Maternal characteristics were age at delivery, maternal education
(low: no, primary, lower vocational, or intermediate secondary
education; middle: intermediate vocational or higher secondary
education; high: higher vocational or academic education), twin
pregnancy (vs. singleton pregnancy), parity (primiparity
vs. multiparity), previous miscarriage, ART, recommended
folic acid use (use of folic acid supplements or multivitamins
containing folic acid from 4 weeks before until 10 weeks
after conception), periconceptional smoking (any smoking),
preexisting diabetes mellitus, and pre-pregnancy body mass
index (BMI). BMI was calculated using the reported weight
(in kilograms) and height (in meters) before conception and
was categorized in four groups (<18.5: underweight; 18.5–24.9:
healthy weight; 25.0–29.9: overweight; and ≥30: obese).
2.3 | Statistical analyses
We used univariable and multivariable logistic regression
analyses to estimate crude and adjusted odds ratios (ORs)
with 95% confidence intervals (95% CIs) for independent
associations between ARM in offspring and maternal
chronic respiratory diseases and antiasthmatic medication
use. To unravel the roles of chronic respiratory diseases and
antiasthmatic medication use, we subdivided the women into
four categories: (a) having a chronic respiratory disease with-
out antiasthmatic medication use, (b) antiasthmatic medication
use without having a chronic respiratory disease, (c) having a
chronic respiratory disease with antiasthmatic medication use,
and (d) having no chronic respiratory disease nor antiasthmatic
medication use (reference group). Antiasthmatic medication
use was subdivided into maintenance use, rescue use, and a
combination of maintenance and rescue use. The type of medi-
cation was not taken into account, only the self-reported fre-
quency of use. We also studied the associations of ARM with
exacerbations in the periconceptional period and with the type
of trigger. We considered year of birth, maternal age at deliv-
ery, maternal education, primiparity, previous miscarriage,
ART, recommended use of folic acid supplements, pericon-
ceptional smoking, and pre-pregnancy BMI as potential con-
founders in the analyses, as these factors were previously
identified as risk factors for ARM or were found to be associ-
ated with ARM in this study.
Potential confounders that changed the crude OR in
bivariable analyses were included in the multivariable models,
from which they were excluded when the OR did not change
more than 10% from the fully adjusted OR upon removal.
Only pre-pregnancy BMI was found to be a true confounder
in the analyses. Statistical analyses were performed using
SPSS 22.0 for Windows (IBM SPSS, Chicago, IL).
3 | RESULTS
In total, we included 412 ARM patients and 2,137 population-
based controls with available maternal questionnaire data. The
majority of ARM patients had a perineal fistula (54%), followed
by rectourethral fistulas (14%), vestibular fistulas (13%), ARM
without fistula (4%), anal stenosis (3%), cloaca (2%), and rare/
other types of ARM (9%). In total, 178 patients (43%) had addi-
tional major birth defects, mainly those that are also part of the
VACTERL association.
No substantial differences were observed between
patients and controls regarding gender, descent, twin preg-
nancies, parity, recommended folic acid supplement use, and
age of the child when completing the questionnaire by the
parents (Table 1). However, both the patients and their
mothers were slightly younger at time of study, and at
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delivery, patients more often had a low birthweight or were
delivered preterm, and patient mothers were lower educated
and more often overweight or obese. In addition, previous
miscarriage, fertility treatment, periconceptional smoking,
and preexisting diabetes mellitus were more frequently
observed in patient mothers, although the differences were
generally small.
Altogether, 102 women were eligible for the telephone
interview (Supporting Information Figure 1). We were able
to reach 77 (75%) of these women and observed 88% agree-
ment between the questionnaire and telephone interview for
the presence of chronic respiratory diseases and 96% agree-
ment for the use of antiasthmatic medication. As mentioned
before, we combined the information from the questionnaire
with the telephone interview.
The risk of ARM seemed to be increased for offspring of
women with chronic respiratory diseases (adjusted OR = 1.6
[0.9–2.6]) (Table 2). In addition, we observed a slightly ele-
vated risk of ARM in offspring of women using antiasthmatic
medication during the periconceptional period (adjusted
OR = 1.4 [0.8–2.6]) (Table 2). When we only considered
medication use during the first 2 months of pregnancy, in
which the hindgut develops, similar results were obtained.
More detailed analyses regarding the pharmaceutical compo-
nents within the antiasthmatic medication was not possible, as
the numbers became too low.
After classification of women according to both their
chronic condition and medication use, we observed higher
risks among women having a chronic respiratory disease,
with and without medication use (adjusted OR = 1.4
[0.8–2.7]) and adjusted OR = 2.0 [0.8–5.0]), both in com-
parison to the women without a chronic respiratory disease
and without medication use (Table 2).The women with
chronic respiratory diseases and medication use did not have
an additional increased risk of ARM in offspring (OR = 0.8
[0.3–2.4]), compared to women with chronic respiratory dis-
eases without medication use. The group of women in the
category that used antiasthmatics without having a chronic
respiratory disease (indications reported were milk allergy,
incidental bronchitis, excessive mucus when waking up, and
unknown in two cases) was too small to draw reliable con-
clusions on the risk of ARM in offspring.
Furthermore, we studied the chronic respiratory diseases
and antiasthmatic medication use more in detail. Women
using their medication on a rescue basis (mainly salbutamol,
a short-acting beta2 agonist), or women who reported a com-
bination of maintenance and rescue use showed increased
risks of ARM in offspring (adjusted OR = 2.4 [0.8–7.3] and
adjusted OR = 2.5 [0.9–6.7]), compared to women without
chronic respiratory diseases and no medication use
(Table 3). The number of women using only maintenance
medication was too small to estimate reliable ORs, but the
percentage of women taking maintenance medication
seemed to be comparable among patients and controls
(0.5 vs. 0.7%).
In addition, especially women with nonallergic triggers or a
combination of allergic and nonallergic triggers seemed to have
increased risks of having a child with ARM (adjusted OR = 2.5
[1.0–6.3] and adjusted OR = 2.4 [0.8–7.0]). In contrast, no
association with ARM in offspring was observed for women
with allergic triggers (adjusted OR = 1.0 [0.3–2.8]). Women
TABLE 1 Characteristics of patients with anorectal malformations, healthy
controls, and their mothers
Patients
(N = 412), N (%)a
Controls
(N = 2,137), N (%)a
Infant characteristics
Boy 201 (48.8) 1,047 (49.0)
Year of birth
≤1990 12 (2.9) 67 (3.1)
1991–1995 79 (19.2) 450 (21.1)
1996–2000 99 (24.0) 538 (25.2)
2001–2005 90 (21.8) 502 (23.5)
2006–2010 110 (26.7) 576 (27.0)
≥2011 22 (5.3) 4 (0.2)
Non-Dutch descent 41 (10.3) 187 (8.8)
Low birthweight (<2,500 g) 64 (16.2) 150 (7.2)
Preterm delivery (<37 weeks) 71 (17.8) 185 (8.8)
Maternal characteristics
Age at delivery
<25 years 30 (7.3) 133 (6.3)
25–29 years 140 (34.0) 658 (30.9)
30–34 years 175 (42.5) 944 (44.4)
≥35 years 67 (16.3) 392 (18.4)
Educational levelb
Low 104 (25.3) 370 (17.4)
Middle 184 (44.8) 982 (46.1)
High 123 (29.9) 780 (36.6)
Twin pregnancy 18 (4.4) 79 (3.7)
Primiparity 193 (46.8) 955 (44.7)
Previous miscarriage 90 (22.1) 405 (19.0)
Assisted reproductive techniques 39 (9.5) 155 (7.3)
No folic acid supplement usec 143 (44.0) 713 (44.4)
Smokingd 107 (26.1) 498 (23.3)
Preexisting diabetes mellitus 10 (2.4) 12 (0.6)
Pre-pregnancy body mass index
Underweight (<18.5 kg/m2) 20 (5.1) 71 (3.5)
Normal (18.5–24.9 kg/m2) 243 (62.3) 1,436 (71.8)
Overweight (25.0–29.9 kg/m2) 87 (22.3) 364 (18.2)
Obese (≥30.0 kg/m2) 40 (10.3) 130 (6.5)
Age child at completion
questionnaire in years,
median (range)
8 (0.0–58.0) 10 (1.0–21.0)
a Numbers do not add up due to missing values (<1% for all variables, except
for low birthweight [2.5%], preterm delivery [1.5%], folic acid use [24.2%,
mainly due to missing values on the exact period of usage], and pre-pregnancy
body mass index [6.2%]).
b Low: no, primary, lower vocational, or intermediate secondary education; mid-
dle: intermediate vocational or higher secondary education; high: higher voca-
tional or academic education.
c In the recommended period (4 weeks before until 10 weeks after conception).
d In the periconceptional period (3 months before until 10 weeks after conception).
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who experienced exacerbations during the periconceptional
period were three times more likely to have a child with ARM
in comparison with the reference group (adjusted OR = 3.2
[1.3–8.0]), whereas no increased risk was observed among
women with chronic respiratory diseases without exacerbations
(adjusted OR = 1.2 [0.5–2.8]). To study the effect of exacerba-
tions independently from rescue medication use, we addition-
ally corrected for the frequency of medication use. This led to
ORs for women with and without exacerbations in the same
order of magnitude (OR = 2.7 [0.8–9.5] and OR = 1.0
[0.3–3.5]).
4 | DISCUSSION
In this study, we tried to disentangle the role of chronic
respiratory diseases and antiasthmatic medication use during
the periconceptional period in the etiology of ARM.
Increased risk estimates of ARM in offspring were observed
for women with chronic respiratory diseases, especially
women without periconceptional antiasthmatic medication
use, in comparison with women who neither have a chronic
respiratory disease nor use antiasthmatic medication. The
risk estimate of ARM in offspring was not increased in
TABLE 2 Associations between anorectal malformations in offspring and maternal chronic respiratory diseases, antiasthmatic medication use during the
periconceptional period, and the combination of both
Patients, N (%) Controls, N (%) Crude ORa (95% CI) Adjusted ORa,b (95% CI)
Presence of CRD
Noc 370 (94.9) 1,940 (97.0) 1.0 1.0
Yes 20 (5.1) 60 (3.0) 1.7 (1.0–2.9) 1.6 (0.9–2.6)
Use of antiasthmatic medication
Noc 376 (96.4) 1,950 (97.6) 1.0 1.0
Yes 14 (3.6) 47 (2.4) 1.5 (0.8–2.8) 1.4 (0.8–2.6)
Combination of CRD and medication used
Neither CRD nor medication usec 369 (94.6) 1,934 (96.8) 1.0 1.0
CRD/no medication use 7 (1.8) 16 (0.8) 2.3 (0.9–5.6) 2.0 (0.8–5.0)
No CRD/medication use 1 (0.3) 4 (0.2) - -
CRD/medication use 13 (3.3) 43 (2.2) 1.6 (0.8–3.0) 1.4 (0.8–2.7)
Notes. The periconceptional period ranges from 3 months before until 10 weeks after conception. CI: confidence interval; CRD: chronic respiratory disease;
OR: odds ratio.
a We did not estimate ORs when <3 patients or controls were exposed.
b Adjusted for pre-pregnancy body mass index.
c Reference category.
d Due to missing values, one patient and four controls could not be categorized in one of the groups.
TABLE 3 Associations between anorectal malformations in offspring and type of antiasthmatic medication used by the mother, type of trigger (allergic
vs. nonallergic) for maternal chronic respiratory diseases, and presence of maternal exacerbations during the periconceptional period
Patients, N (%) Controls, N (%) Crude ORa (95% CI) Adjusted ORa,b (95% CI)
Type of antiasthmatic medicationc
Neither CRD nor medicationd 373 (96.6) 1,945 (98.3) 1.0 1.0
Maintenance use 2 (0.5) 13 (0.7) - -
Rescue use 5 (1.3) 9 (0.5) 2.9 (1.0–8.7) 2.4 (0.8–7.3)
Maintenance and rescue use 6 (1.6) 12 (0.6) 2.6 (1.0–7.0) 2.5 (0.9–6.7)
Type of triggere
No CRDd 369 (95.8) 1,935 (97.8) 1.0 1.0
Allergic 4 (1.0) 20 (1.0) 1.0 (0.4–3.1) 1.0 (0.3–2.8)
Nonallergic 7 (1.8) 13 (0.7) 2.8 (1.1,7.1) 2.5 (1.0–6.3)
Allergic and non-allergic 5 (1.3) 11 (0.6) 2.4 (0.8–6.9) 2.4 (0.8–7.0)
Presence of exacerbationsf
No CRDd 369 (96.1) 1,934 (97.9) 1.0 1.0
No 7 (1.8) 29 (1.5) 1.3 (0.6–2.9) 1.2 (0.5–2.8)
Yes 8 (2.1) 12 (0.6) 3.5 (1.4–8.6) 3.2 (1.3–8.0)
Notes. The periconceptional period ranges from 3 months before until 10 weeks after conception. CI: confidence interval; CRD: chronic respiratory disease;
OR: odds ratio.
a We did not calculate ORs when <3 patients or controls were exposed.
b Adjusted for pre-pregnancy body mass index.
c Due to missing values, five patients and 23 controls could not be categorized.
d Reference category.
e Due to missing values, six patients and 23 controls could not be categorized.
f Due to missing values, seven patients and 27 controls could not be categorized.
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women with chronic respiratory diseases who used antiasth-
matic medication, compared to women with chronic respira-
tory diseases without medication use. Furthermore,
increased risk estimates of ARM in offspring were observed
in particular among women using their medication on a res-
cue basis, women having nonallergic triggers, and women
having exacerbations during the periconceptional period.
Although all but one of the 95% CIs contained the null
value, these associations all suggest an association between
ARM in offspring and an uncontrolled chronic respiratory
disease state.
A strength of this study was the large number of repre-
sentative and well-characterized ARM patients and compara-
ble population-based controls. After applying several
exclusion criteria, we observed additional birth defects in
43% of the patients, which corresponds with previous studies
reporting 40–70% of ARM patients having additional birth
defects (Cuschieri & EurocatWorkingGroup, 2002; Stoll
et al., 2007; Wijers et al., 2013). Moreover, the distribution
of ARM subtypes in our study was comparable with patients
from the European ARM-Net registry (de Blaauw et al.,
2013). The population-based controls were representative
for the source population of the patients as they were ran-
domly selected from the same geographical areas as the
patients and were of similar age. There remains a possibility
that the controls did not participate in a way that they
remained representative after inclusion. However, most of
their representative characteristics are similar to the general
Dutch pregnant population (Wijers, de Blaauw, et al., 2014).
Another strength is that we conducted a telephone inter-
view to obtain more detailed information about the chronic
respiratory diseases and the periconceptional antiasthmatic
medication use, enabling us to perform more in-depth ana-
lyses. A limitation, however, is that we only interviewed
women who reported chronic respiratory diseases or anti-
asthmatic medication use and women for whom this infor-
mation was unclear in the questionnaire. As it was not
feasible to also contact women who did not report positively
on either of these variables, the presence of chronic respira-
tory diseases might have been underreported. However, we
assume this is unlikely, as 98% agreement was observed for
not reporting respiratory diseases in a study comparing
obstetric records and questionnaires completed by pregnant
women (van Gelder et al., 2015).
Another limitation was the possibility for recall bias, as
the risk factors included in our study were self-reported and
especially because parents were asked to recall circumstances
that occurred some time ago. The median age of the children
at the time of filling out the questionnaire was a little bit lower
in patients (8 years, range 0–58 years) than in controls
(10 years, range 0–21 years; Table 1). Among the patients,
there was only 1 patient with 58 years between childbirth and
filling out the questionnaire; by excluding this outlier, the
range is 0–22 years. Because of the small differences between
patients and controls, and the fact that this variable was not
a confounder in our analyses, we expect that differential
misclassification due to recall times is minimal.
The prevalence of chronic respiratory diseases in the peri-
conceptional period was only 3% among control mothers
(vs. 5% in patient mothers). These numbers are lower than the
general rate of these conditions in the Netherlands in 2016,
approximately 6% (CBS, 2016), which is similar to the num-
bers reported in the United States (4–8%) (Kwon et al., 2003;
Murphy, 2015). However, Kwon et al. demonstrated that the
rate of asthma among pregnant women varies with time, pop-
ulation, and method of data collection (Kwon et al., 2003).
According to the National Health Interview Survey for the
time period 1997–2000, the total prevalence was 4%, com-
pared to 8% in the time period 2000–2001 with the Behavior
Risk Factor Surveillance System (Kwon et al., 2003). The rel-
atively low prevalence of chronic respiratory diseases in our
study may partly be explained by the fact that almost 50% of
the women were pregnant before 2000. Unfortunately, we
were not able to stratify by time to study whether timing is
associated with the exposure, as the numbers will become too
small to draw any reliable conclusions. In addition, it is possi-
ble that some women did have a chronic respiratory disease
during childhood but did not experience any symptoms during
pregnancy. The resulting underreporting is likely to be similar
for our patient and control population, as maternal chronic
respiratory diseases and associated exacerbations are not gen-
erally known as risk factors for birth defects, which may have
resulted in an underestimation of the real effect.
Both antiasthmatic medication use and chronic respiratory
diseases show increased risk estimates of ARM in offspring
in the current study. Our risk estimates for the effects of anti-
asthmatic medication use on ARM in offspring (adjusted
OR = 1.4 [0.8–2.6]) were comparable to those found in the
studies by Kallen & Otterblad Olausson (2007) and Kallen
(2014). Lin et al. (2012) detected a twofold increased risk of
ARM in offspring, however, in isolated ARM and for anti-
inflammatory medication only. Garne et al. (2016) showed a
threefold increased risk of ARM in offspring, but this study
was conducted for inhaled corticosteroids only. For chronic
respiratory diseases, Wijers et al. (2013) showed similar risks
for chronic obstructive lower pulmonary diseases in a
registry-based study, compared to our risk estimate (adjusted
OR = 1.6 [0.9–2.6]. Remarkably, Zwink et al. (2016) showed
a 30-fold increased risk of ARM in offspring for maternal
chronic respiratory. The large difference with our study may
be due to their inclusion of allergy to grass, pollen, or animal
hair as respiratory diseases, whereas we did not include these
allergies to limit heterogeneity. Based on the above-
mentioned results, we conclude that our study is in line with
the existing literature. However, we went one step further by
unraveling the effects of chronic respiratory diseases from
those of medication use.
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In our study, we observed elevated risk estimates for
women who had chronic respiratory diseases and for women
who used antiasthmatic medication, although the 95% CI did
include the null value. In addition, women with a chronic
respiratory disease without antiasthmatic medication use had
the highest risk estimate of ARM in offspring. One could
argue that these women stopped using their medication
because they experienced fewer symptoms. However, the
argument that we most often heard during the telephone
interview was that women stopped using their medication
because they were afraid to harm their unborn child.
When we compared women with chronic respiratory dis-
eases with and without medication use, no additional
elevated risk was observed. Therefore, the results indicate
that the chronic respiratory disease itself seems to be associ-
ated with ARM in offspring and not the associated medication
use. However, were not able to draw any conclusions based
on this information only.
The telephone interviews helped us to obtain more
detailed information to support our findings of the chronic
respiratory disease being responsible. Especially women who
used rescue medication, had nonallergic triggers, and experi-
enced exacerbations during the periconceptional period had
increased risk estimates of ARM in offspring. To study the
independent effect of exacerbations, we corrected for the fre-
quency of medication use. However, we found results in the
same order of magnitude, indicating that the increased ORs
among women experiencing exacerbations can be attributed
to the exacerbations itself and not to the use of rescue medica-
tion. Both, the presence of exacerbations and the use of rescue
medication point toward uncontrolled chronic respiratory
diseases. In addition, nonallergic triggers, such as weather
conditions, viral infections, and outdoor and indoor pollutants,
are generally harder to avoid than allergic triggers; therefore,
women may also experience more problems with controlling
their chronic respiratory disease. Although the CIs for rescue
medication, a combination of rescue and maintenance medi-
cation, and nonallergic triggers do contain the null value,
possibly due to small numbers, their lower limits were very
close to 1, and they all point in the same direction. There-
fore, we conclude that these results suggest that uncontrolled
chronic respiratory diseases may be associated with ARM in
offspring. Blais et al. showed that women with exacerbations
are two times more likely to have a child with a major birth
defect, after exclusion of women using oral corticosteroids
(Blais & Forget, 2008). This study is in line with our finding
that especially the underlying uncontrolled chronic respira-
tory disease seems responsible for the increased risks of
ARM in offspring.
Proposed mechanisms for adverse pregnancy outcomes in
women with an uncontrolled chronic respiratory disease are, for
example, maternal hypoxia or the release of inflammation medi-
ators (Blais et al., 2010; Murphy, Gibson, Smith, & Clifton,
2005). Previous studies showed that the number of interferon-
gamma-producing cells and the levels of circulating heat shock
protein-70 were increased in asthmatic women compared to
women experiencing an “uncomplicated” pregnancy, and that
this increase was associated with fetal growth restriction
(Tamasi et al., 2005; Tamasi et al., 2010). Maternal hypoxia
might lead to adverse effects due to impaired fetal oxygenation
(National Asthma Education and Prevention Program Asthma
and Pregnancy Working Group, 2005). It is very important to
mention that both of these hypothesized mechanisms might not
only play a role in disturbing anorectal development but also
the embryonic development of other organ systems. Therefore,
we believe it is important to study the role of this newly identi-
fied risk factor in more detail.
In conclusion, even with the low frequency of women
experiencing chronic respiratory diseases, our results suggest
the involvement of uncontrolled maternal chronic respiratory
diseases, with or without the use of rescue medication to
alleviate exacerbations, in the development of ARM in off-
spring. This study suggested the involvement of uncontrolled
maternal chronic diseases as a new mechanism in the etiology
of birth defects that requires more in depth-studies among
larger groups of patients with all kinds of birth defects.
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